Axsome Therapeutics (AXSM) Current Leases (2020 - 2026)

Axsome Therapeutics has reported Current Leases for 7 years, with the latest figure at $3.2 million in Q1 2026.

• Quarterly Current Leases rose 603.3% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 603.3% YoY) and the FY2025 annual result came in at $2.5 million, up 38.69% from the prior year.
• Current Leases improved to $3.2 million in Q1 2026 per AXSM's latest filing, from $2.5 million in the prior quarter.
• Over five years, Current Leases peaked at $3.2 million in Q1 2026 and troughed at $108000.0 in Q1 2023.
• A 5-year average of $1.1 million and a median of $709120.0 in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2023 and 2026: Current Leases slumped 88.83% in 2023, then jumped 603.3% in 2026.
• Over 5 years, Current Leases stood at $425000.0 in 2022, then soared by 198.12% to $1.3 million in 2023, then surged by 44.83% to $1.8 million in 2024, then surged by 38.69% to $2.5 million in 2025, then grew by 25.46% to $3.2 million in 2026.
• According to Business Quant data, Current Leases over the past three periods registered $3.2 million, $2.5 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.